Company Filing History:
Years Active: 2010-2024
Title: Jon Andre Erickson - Innovator in Pharmaceutical Solutions
Introduction
Jon Andre Erickson is an accomplished inventor based in Carmel, Indiana, renowned for his contributions to the pharmaceutical field. With a total of three patents to his name, his work focuses on innovative treatments targeting various medical conditions.
Latest Patents
Erickson's latest patents include significant advancements in the development of ATR antagonists. One of his notable inventions involves certain piperidine compounds that demonstrated efficacy as ATR antagonists. Specifically, his work on pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives is aimed at treating psoriasis and systemic lupus erythematosus. This invention provides a compound that features modifications where R can be methyl or ethyl, or its pharmaceutically acceptable salts, contributing to the development of effective therapies for challenging autoimmune diseases.
Career Highlights
Currently, Jon Andre Erickson is employed by Eli Lilly and Company, a leading global pharmaceutical firm. His role within Eli Lilly has allowed him to impact drug development significantly, particularly in the discovery of novel compounds that address unmet medical needs. With a strong focus on research and development, Erickson has made strides that are recognized in the scientific community.
Collaborations
Throughout his career, Jon Erickson has collaborated with fellow innovators and researchers, including Howard Barff Broughton and Robert Dean Dally. These partnerships have been pivotal in advancing his projects and enhancing the overall innovation landscape within the pharmaceutical industry.
Conclusion
In conclusion, Jon Andre Erickson is a prolific inventor whose work in developing ATR antagonists has the potential to transform treatment modalities for psoriasis and systemic lupus erythematosus. His commitment to innovation and collaboration within Eli Lilly and Company underscores the importance of teamwork in advancing medical science and improving patient outcomes.